SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Tarsus Pharmaceuticals (TARS) Reports XDEMVY Sales of $194.6M, Up Approximately 64%

Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6M, up about 64% from a year earlier. Cumulative sales since launch passed $1B, over 1 million bottles were dispensed, and Neera Clase was appointed Chief Commercial Officer.

Published:

Updated:

What happened

Tarsus Pharmaceuticals said third-quarter XDEMVY sales rose about 64% from a year earlier to $194.6 million, and it raised its fiscal 2026 sales guidance. It also reported a $668.3 million quarterly loss, including $632.2 million in research spending tied to acquired programs.

Global impact / market context

Strong sales and higher guidance may support confidence in XDEMVY’s growth. But the large reported loss shows that acquired research spending can weigh heavily on results. No verified market reactions were supplied.

What to watch

  1. Check the next XDEMVY sales report to see whether growth continues, because recent sales drove the higher guidance.
  2. Check future reports for acquired research spending, because it contributed to the quarterly loss.
  3. Check updates on the approaching clinical milestones, because they may show how the company’s pipeline programs are progressing.

Affected assets

  • Tarsus Pharmaceuticals, Inc.
  • XDEMVY (lotilaner ophthalmic solution)

Evidence